Table 1

ALK-positive NSCLC patients with acquired resistance to crizotinib. Adeno, adenocarcinoma; NA, tissue not available; BAC, bronchioloalveolar component.

PatientDuration
(months)*
Timing
(months)
HistologyALK
fusion
ALK-amplifiedALK mutationPhospho-EGFR
(pre-crizotinib)
Phospho-EGFR
(post-crizotinib)
CKIT FISH
MGH0NZ200AdenoPositiveNoNo1+1+ (solid)
2+ (BAC)
Amplified (solid)
MGH00143.5AdenoPositiveNoNoNA1+No
MGH01080AdenoPositiveNoNo2+1+No
MGH011340AdenoPositiveNoS1206Y2+2+No
MGH01390AdenoPositiveNoNoNA2+No
MGH01666AdenoPositiveNoNo1+2+No
MGH01723+0AdenoPositiveNoNo02+No
MGH018100.5AdenoPositiveNoG1202R2+2+Focal amplification
MGH0198<0.5AdenoPositiveNoNoNANANA
MGH020130AdenoPositiveNoL1196MNANANA
MGH021123AdenoPositiveNo1151Tins1+2+No
MGH02260AdenoPositiveNoNoNA2+No
MGH023120AdenoPositiveNoNo2+1+No
MGH024150AdenoPositiveNoNo2+2+No
MGH025110AdenoNANANoNA2+No
MGH02741AdenoNANANoNANANA
MGH028141AdenoNANANo1+NANA
MGH02980AdenoPositiveYesNoNA0NA

*Approximate duration of crizotinib therapy. “+” indicates that the patient remains on crizotinib.

†Approximate time between the last crizotinib dose and the repeat biopsy. “0” indicates that the patient was still taking crizotinib at the time of the biopsy.

‡This sample had focal areas with 2+ staining.